Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

NCT ID: NCT00408408

Last Updated: 2017-09-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 1206 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2018-03-31

Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy and bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known which chemotherapy regimen is more effective with or without bevacizumab in treating breast cancer.

PURPOSE: This randomized phase III trial is studying six different chemotherapy regimens to compare how well they work with or without bevacizumab in treating women with stage I, stage II, or stage IIIA breast cancer that can be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

• Compare the efficacy of docetaxel followed by doxorubicin hydrocloride and cyclophosphamide (AC) vs docetaxel and capecitabine followed by AC vs docetaxel and gemcitabine hydrochloride followed by AC, with or without bevacizumab, in terms of an increase in the rate of pathologic complete response (pCR) in the breast, in women with palpable or operable breast cancer.

Secondary

• Compare docetaxel/capecitabine with AC vs docetaxel/gemcitabine hydrochloride with AC vs docetaxel with AC, with or without bevacizumab, in terms of the rate of pCR in the breast and all post-therapy lymph nodes evaluated histologically (pCR breast and nodes).
• Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based regimens (docetaxel with AC, docetaxel and capecitabine with AC, and docetaxel and gemcitabine hydrochloride with AC) will increase the rate of pCR of the breast and nodes compared to the same docetaxel/anthracycline-based regimens without bevacizumab in these patients.
• Determine whether the addition of capecitabine or gemcitabine hydrochloride to docetaxel, with or without bevacizumab, will increase the rate of clinical overall response (cOR) compared to docetaxel alone with or without bevacizumab in these patients.
• Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based regimens will increase the rate of cOR compared to the same docetaxel/anthracycline-based regimens without bevacizumab in these patients.
• Determine whether the addition of capecitabine or gemcitabine hydrochloride to docetaxel, with or without bevacizumab, will increase the rate of clinical complete response (cCR) compared to docetaxel alone with or without bevacizumab in these patients.
• Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based regimens (docetaxel with AC, docetaxel/capecitabine with AC, and docetaxel/gemcitabine hydrochloride with AC) will increase the rate of cCR compared to the same docetaxel/anthracycline-based regimens without bevacizumab in these patients.
• Identify gene expression profiles that can predict pCR in patients treated with the different sequential docetaxel/anthracycline-based regimens with or without bevacizumab.
• Identify gene expression profiles that can predict cOR in patients treated with docetaxel alone, docetaxel/capecitabine, or docetaxel/gemcitabine hydrochloride with or without bevacizumab.
• Determine the accuracy of an in vitro chemoresponse assay (ChemoFx®) as a predictor of pCR in patients treated with the different sequential docetaxel/anthracycline-based regimens without bevacizumab.
• Determine the accuracy of ChemoFx® as a predictor of cOR in patients treated with docetaxel alone, docetaxel/capecitabine, or docetaxel/gemcitabine hydrochloride without bevacizumab in these patients.
• Determine the impact of preoperative bevacizumab and sequential chemotherapy regimens and postoperative bevacizumab therapy on cardiac function in these patients.
• Determine the impact of bevacizumab on surgical complications in these patients.
• Determine the toxicity of the preoperative regimens and the toxicity of postoperative bevacizumab in these patients.
• Compare the docetaxel/anthracycline-based regimens with vs without bevacizumab, in terms of an increase in disease-free survival, of these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor size (2-4 cm vs > 4 cm), nodal status (negative vs positive), hormone receptor status (estrogen receptor [ER]-positive and/or progesterone-receptor [PgR]-positive vs ER- and PgR-negative), and age (< 50 years vs ≥ 50 years). Patients are randomized to 1 of 6 treatment arms.

Core needle biopsies are performed at baseline. Tumor tissue samples are also collected during definitive surgery. Samples are examined for gene expression and polymorphism by reverse transcriptase-polymerase chain reaction analysis and chemoresponse assay (ChemoFx®).

After completion of study therapy, patients are followed periodically for 10 years.

PROJECTED ACCRUAL: A total of 1,200 patients will be accrued for this study.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 3B: Docetaxel + Gem + Bev then AC + Bev

Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.

Group Type: EXPERIMENTAL

bevacizumab

Intervention Type: BIOLOGICAL

15 mg/kg IV

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

gemcitabine hydrochloride

Intervention Type: DRUG

1000 mg/m2 IV

Arm 1A: Docetaxel then AC

Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).

Group Type: ACTIVE_COMPARATOR

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

Arm 1B Docetaxel + Bev then AC + Bev

Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

bevacizumab

Intervention Type: BIOLOGICAL

15 mg/kg IV

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

Arm 2A: Docetaxel + Capecitabine then AC

Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.

Group Type: EXPERIMENTAL

capecitabine

Intervention Type: DRUG

825 mg/m2 orally

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

Arm 2B: Docetaxel + Cape + Bev then AC + Bev

Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.

Group Type: EXPERIMENTAL

bevacizumab

Intervention Type: BIOLOGICAL

15 mg/kg IV

capecitabine

Intervention Type: DRUG

825 mg/m2 orally

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

Arm 3A: Docetaxel + Gem then AC

Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.

Group Type: EXPERIMENTAL

cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV

docetaxel

Intervention Type: DRUG

100 mg/m2 IV

doxorubicin hydrochloride (Adriamycin)

Intervention Type: DRUG

60 mg/m2 IV

gemcitabine hydrochloride

Intervention Type: DRUG

1000 mg/m2 IV

Interventions

bevacizumab

15 mg/kg IV

Intervention Type: BIOLOGICAL

capecitabine

825 mg/m2 orally

Intervention Type: DRUG

cyclophosphamide

600 mg/m2 IV

Intervention Type: DRUG

docetaxel

100 mg/m2 IV

Intervention Type: DRUG

doxorubicin hydrochloride (Adriamycin)

60 mg/m2 IV

Intervention Type: DRUG

gemcitabine hydrochloride

1000 mg/m2 IV

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The patient must have consented to participate and must have signed and dated an appropriate Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines for the study treatment and submission of pre-entry core biopsy material for correlative studies.
• Patients must be female.
• Patients must be 18 years of age or older.
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy.
• The primary breast tumor must be palpable and measure greater than or equal to 2.0 cm on physical exam.
• All patients must have their left ventricular ejection fraction (LVEF) assessed by multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study entry. The LVEF must be greater than or equal to the lower limit of normal (LLN) for the cardiac imaging facility performing the study. Note: If the cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.

• Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if bevacizumab therapy can be continued, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 75%, the investigator should have the study reviewed for accuracy prior to study entry. Following study entry, the LVEF determination may be reviewed up until the time of the post-chemotherapy (preoperative) evaluation. Please note that if a more accurate value is obtained from the review of the baseline MUGA or echocardiogram, the correct value must be submitted to the NSABP before the post-chemotherapy (preoperative) MUGA or echocardiogram is performed or it cannot be used for managing postoperative bevacizumab.
• All patients must have an EKG within 3 months prior to study entry.
• At the time of randomization:

• Absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3.
• Platelet count must be greater than or equal to 100,000/mm3.
• Hemoglobin must be greater than or equal to 10 g/dL.
• There must be evidence of adequate hepatic function by these criteria:
• Total bilirubin must be less than or equal to the ULN for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) resulting from Gilbert's disease or similar syndrome due to slow conjugation of bilirubin; and
• Alkaline phosphatase must be less than or equal 2.5 x ULN for the lab; and
• Aspartate Aminotransferase (AST) must be less than or equal to 1.5 x ULN for the lab.
• Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than or equal 2.5 x ULN, then the AST must be less than or equal the ULN. If the AST is greater than the ULN but less than or equal 1.5 x ULN, then the alkaline phosphatase must be less than or equal ULN.
• Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal 2.5 x ULN are eligible for inclusion in the study if bone scans do not demonstrate metastatic disease. Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy.
• Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging does not demonstrate metastatic disease and adequate bone marrow and liver function results as described above are met.
• The following criteria for evidence of adequate renal function must be met:
• Serum creatinine less than or equal ULN for the lab.
• Calculated creatinine clearance must be greater than 50 mL/min.
• Urine protein/urine creatinine (UPC) ratio must be less than 1.0.
• Patient must be able to swallow oral medications.

Exclusion Criteria

• Tumor determined to be strongly human epidermal growth factor receptor 2 (HER2)-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).
• Excisional or incisional biopsy for this primary breast tumor.
• Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine Needle Aspiration (FNA) or core biopsy of an axillary node is permitted for any patient, and 2) although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted.
• Tumors clinically staged as T4.
• Ipsilateral cN2b or cN3 disease. (Patients with cN1 or cN2a disease are eligible.)
• Definitive clinical or radiologic evidence of metastatic disease.
• Synchronous bilateral breast cancer (invasive or DCIS).
• Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entry.
• Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. (These patients are eligible if this therapy is discontinued prior to randomization.)
• Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. (Patients are eligible only if these medications are discontinued prior to randomization.)
• Prior history of breast cancer, including DCIS. (Patients with a history of lobular carcinoma in situ [LCIS] are eligible.)
• Prior therapy with anthracyclines, taxanes, capecitabine, 5-FU (fluorouracil), gemcitabine, or bevacizumab for any malignancy.
• Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by her physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
• Cardiac disease that would preclude the use of anthracyclines. This includes:

• angina pectoris that requires the use of anti-anginal medication;
• history of documented congestive heart failure;
• serious cardiac arrhythmia requiring medication;
• severe conduction abnormality;
• valvular disease with documented cardiac function compromise; and
• uncontrolled hypertension defined as BP greater than 150/90 on antihypertensive therapy. (Patients with hypertension that is well controlled on medication are eligible.)
• History of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function.
• History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).
• History of other arterial thrombotic event within 12 months before study entry.
• Symptomatic peripheral vascular disease.
• Any significant non-traumatic bleeding within 6 months before study entry.
• Serious or non-healing wound, skin ulcers, or incompletely healed bone fracture.
• Gastroduodenal ulcer(s) determined by endoscopy to be active.
• Invasive procedures defined as follows:

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure.)
• Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of the study.
• Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range international normalized ratio [INR] [usually between 2 and 3] are eligible.)
• Sensory/motor neuropathy greater than or equal grade 2, as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).
• Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up.
• Conditions that would prohibit administration of corticosteroids.
• History of severe hypersensitivity reaction to drugs formulated with polysorbate 80.
• Administration of any investigational agents within 30 days before study entry.
• Pregnancy or lactation at the time of proposed randomization.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

NSABP Foundation Inc

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Norman Wolmark, MD

Role: PRINCIPAL_INVESTIGATOR

NSABP Foundation Inc

Locations

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

East Bay Radiation Oncology Center

Castro Valley, California, United States

Eden Medical Center

Castro Valley, California, United States

Valley Medical Oncology Consultants - Castro Valley

Castro Valley, California, United States

Kaiser Permanente - Fremont

Fremont, California, United States

Valley Medical Oncology

Fremont, California, United States

Cancer Care Associates

Fresno, California, United States

Kaiser Permanente Medical Center - Hayward

Hayward, California, United States

Scripps Cancer Center - San Diego

La Jolla, California, United States

Loma Linda University Cancer Institute at Loma Linda University Medical Center

Loma Linda, California, United States

Contra Costa Regional Medical Center

Martinez, California, United States

El Camino Hospital Cancer Center

Mountain View, California, United States

Highland General Hospital

Oakland, California, United States

Alta Bates Summit Medical Center - Summit Campus

Oakland, California, United States

Bay Area Breast Surgeons, Incorporated

Oakland, California, United States

CCOP - Bay Area Tumor Institute

Oakland, California, United States

Larry G Strieff MD Medical Corporation

Oakland, California, United States

Tom K Lee, Incorporated

Oakland, California, United States

Kaiser Permanente Medical Center - Oakland

Oakland, California, United States

St. Joseph Hospital Regional Cancer Center - Orange

Orange, California, United States

Desert Regional Medical Center Comprehensive Cancer Center

Palm Springs, California, United States

Valley Care Medical Center

Pleasanton, California, United States

Valley Medical Oncology Consultants - Pleasanton

Pleasanton, California, United States

Kaiser Permanente Medical Center - Redwood City

Redwood City, California, United States

Kaiser Permanente Medical Center - Richmond

Richmond, California, United States

Kaiser Permanente Medical Center - Roseville

Roseville, California, United States

South Sacramento Kaiser-Permanente Medical Center

Sacramento, California, United States

Kaiser Permanente Medical Center - Sacramento

Sacramento, California, United States

Salinas Valley Memorial Hospital

Salinas, California, United States

Kaiser Permanente Medical Office -Vandever Medical Office

San Diego, California, United States

Kaiser Permanente Medical Center - San Francisco Geary Campus

San Francisco, California, United States

Kaiser Permanente Medical Center - Santa Teresa

San Jose, California, United States

Doctors Medical Center - San Pablo Campus

San Pablo, California, United States

Kaiser Foundation Hospital - San Rafael

San Rafael, California, United States

Kaiser Permanente Medical Center - Santa Clara Kiely Campus

Santa Clara, California, United States

Kaiser Permanente Medical Center - Santa Rosa

Santa Rosa, California, United States

Kaiser Permanente Medical Center - South San Francisco

South San Francisco, California, United States

Kaiser Permanente Medical Facility - Stockton

Stockton, California, United States

Kaiser Permanente Medical Center - Vallejo

Vallejo, California, United States

Kaiser Permanente Medical Center - Walnut Creek

Walnut Creek, California, United States

Aurora Presbyterian Hospital

Aurora, Colorado, United States

Boulder Community Hospital

Boulder, Colorado, United States

Memorial Hospital Cancer Center - Colorado Springs

Colorado Springs, Colorado, United States

Penrose Cancer Center at Penrose Hospital

Colorado Springs, Colorado, United States

St. Anthony Central Hospital

Denver, Colorado, United States

Kaiser Permanente - Denver

Denver, Colorado, United States

Porter Adventist Hospital

Denver, Colorado, United States

Presbyterian - St. Luke's Medical Center

Denver, Colorado, United States

St. Joseph Hospital

Denver, Colorado, United States

Rose Medical Center

Denver, Colorado, United States

CCOP - Colorado Cancer Research Program

Denver, Colorado, United States

Swedish Medical Center

Englewood, Colorado, United States

St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

Grand Junction, Colorado, United States

North Colorado Medical Center

Greeley, Colorado, United States

Kaiser Permanente - Lafayette

Lafayette, Colorado, United States

Sky Ridge Medical Center

Lone Tree, Colorado, United States

Hope Cancer Care Center at Longmont United Hospital

Longmont, Colorado, United States

McKee Medical Center

Loveland, Colorado, United States

St. Mary - Corwin Regional Medical Center

Pueblo, Colorado, United States

North Suburban Medical Center

Thornton, Colorado, United States

Exempla Lutheran Medical Center

Wheat Ridge, Colorado, United States

Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

Farmington, Connecticut, United States

Helen and Harry Gray Cancer Center at Hartford Hospital

Hartford, Connecticut, United States

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Hartford, Connecticut, United States

Eastern Connecticut Hematology and Oncology Associates

Norwich, Connecticut, United States

Tunnell Cancer Center at Beebe Medical Center

Lewes, Delaware, United States

CCOP - Christiana Care Health Services

Newark, Delaware, United States

Sibley Memorial Hospital

Washington D.C., District of Columbia, United States

Herbert D. Kerman Regional Oncology Center - Daytona Beach

Daytona Beach, Florida, United States

Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital

Fort Lauderdale, Florida, United States

Broward General Medical Center Cancer Center

Fort Lauderdale, Florida, United States

Baptist Cancer Institute - Jacksonville

Jacksonville, Florida, United States

Ella Milbank Foshay Cancer Center at Jupiter Medical Center

Jupiter, Florida, United States

CCOP - Mount Sinai Medical Center

Miami Beach, Florida, United States

Florida Hospital Cancer Institute at Florida Hospital Orlando

Orlando, Florida, United States

M.D. Anderson Cancer Center at Orlando

Orlando, Florida, United States

Phoebe Cancer Center at Phoebe Putney Memorial Hospital

Albany, Georgia, United States

Northeast Georgia Medical Center

Gainesville, Georgia, United States

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

Savannah, Georgia, United States

Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler

Savannah, Georgia, United States

Cancer Research Center of Hawaii

Honolulu, Hawaii, United States

OnCare Hawaii, Incorporated - Lusitana

Honolulu, Hawaii, United States

Queen's Cancer Institute at Queen's Medical Center

Honolulu, Hawaii, United States

Straub Clinic and Hospital, Incorporated

Honolulu, Hawaii, United States

Hawaii Medical Center - East

Honolulu, Hawaii, United States

OnCare Hawaii, Incorporated - Kuakini

Honolulu, Hawaii, United States

Kaiser Permanente - Moanalua Medical Center and Clinic

Honolulu, Hawaii, United States

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, United States

Maui Memorial Medical Center

Wailuku, Hawaii, United States

Pacific Cancer Institute - Maui

Wailuku, Hawaii, United States

Kapiolani Medical Center at Pali Momi

‘Aiea, Hawaii, United States

Kootenai Cancer Center - Coeur d'Alene

Coeur d'Alene, Idaho, United States

Saint Anthony's Hospital at Saint Anthony's Health Center

Alton, Illinois, United States

Illinois CancerCare - Bloomington

Bloomington, Illinois, United States

St. Joseph Medical Center

Bloomington, Illinois, United States

Graham Hospital

Canton, Illinois, United States

Illinois CancerCare - Canton

Canton, Illinois, United States

Illinois CancerCare - Carthage

Carthage, Illinois, United States

Memorial Hospital

Carthage, Illinois, United States

Mount Sinai Hospital Medical Center

Chicago, Illinois, United States

John H. Stroger, Jr. Hospital of Cook County

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

Decatur Memorial Hospital Cancer Care Institute

Decatur, Illinois, United States

Alexian Brothers Radiation Oncology

Elk Grove Village, Illinois, United States

Eureka Community Hospital

Eureka, Illinois, United States

Illinois CancerCare - Eureka

Eureka, Illinois, United States

St. Francis Hospital

Evanston, Illinois, United States

Galesburg Clinic, PC

Galesburg, Illinois, United States

Galesburg Cottage Hospital

Galesburg, Illinois, United States

Illinois CancerCare - Cottage

Galesburg, Illinois, United States

Illinois CancerCare - Galesburg

Galesburg, Illinois, United States

Illinois CancerCare - Havana

Havana, Illinois, United States

Mason District Hospital

Havana, Illinois, United States

Illinois CancerCare - Kewanee Clinic

Kewanee, Illinois, United States

Illinois CancerCare - Macomb

Macomb, Illinois, United States

McDonough District Hospital

Macomb, Illinois, United States

Cardinal Bernardin Cancer Center at Loyola University Medical Center

Maywood, Illinois, United States

Illinois CancerCare - Monmouth

Monmouth, Illinois, United States

OSF Holy Family Medical Center

Monmouth, Illinois, United States

Good Samaritan Regional Health Center

Mount Vernon, Illinois, United States

Edward Hospital Cancer Center

Naperville, Illinois, United States

BroMenn Regional Medical Center

Normal, Illinois, United States

Community Cancer Center

Normal, Illinois, United States

Illinois CancerCare - Community Cancer Center

Normal, Illinois, United States

Community Hospital of Ottawa

Ottawa, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Ottawa

Ottawa, Illinois, United States

Illinois CancerCare - Pekin

Pekin, Illinois, United States

Proctor Hospital

Peoria, Illinois, United States

CCOP - Illinois Oncology Research Association

Peoria, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Peoria

Peoria, Illinois, United States

Methodist Medical Center of Illinois

Peoria, Illinois, United States

OSF St. Francis Medical Center

Peoria, Illinois, United States

Illinois CancerCare - Peru

Peru, Illinois, United States

Illinois Valley Community Hospital

Peru, Illinois, United States

Illinois CancerCare - Princeton

Princeton, Illinois, United States

Perry Memorial Hospital

Princeton, Illinois, United States

Swedish-American Regional Cancer Center

Rockford, Illinois, United States

Illinois CancerCare - Spring Valley

Spring Valley, Illinois, United States

Regional Cancer Center at Memorial Medical Center

Springfield, Illinois, United States

St. Francis Hospital and Health Centers - Beech Grove Campus

Beech Grove, Indiana, United States

Elkhart Clinic, LLC

Elkhart, Indiana, United States

Elkhart General Hospital

Elkhart, Indiana, United States

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States

Center for Cancer Care at Goshen General Hospital

Goshen, Indiana, United States

St. Vincent Indianapolis Hospital

Indianapolis, Indiana, United States

Howard Community Hospital

Kokomo, Indiana, United States

Center for Cancer Therapy at LaPorte Hospital and Health Services

La Porte, Indiana, United States

Community Hospital

Munster, Indiana, United States

Reid Hospital & Health Care Services

Richmond, Indiana, United States

CCOP - Northern Indiana CR Consortium

South Bend, Indiana, United States

Memorial Hospital of South Bend

South Bend, Indiana, United States

Michiana Hematology-Oncology, PC - South Bend

South Bend, Indiana, United States

Saint Joseph Regional Medical Center

South Bend, Indiana, United States

South Bend Clinic

South Bend, Indiana, United States

McFarland Clinic, PC

Ames, Iowa, United States

Holden Comprehensive Cancer Center at University of Iowa

Iowa City, Iowa, United States

Cancer Center of Kansas, PA - Chanute

Chanute, Kansas, United States

Cancer Center of Kansas, PA - Dodge City

Dodge City, Kansas, United States

Cancer Center of Kansas, PA - El Dorado

El Dorado, Kansas, United States

Cancer Center of Kansas - Fort Scott

Fort Scott, Kansas, United States

Cancer Center of Kansas-Independence

Independence, Kansas, United States

Cancer Center of Kansas, PA - Kingman

Kingman, Kansas, United States

Lawrence Memorial Hospital

Lawrence, Kansas, United States

Southwest Medical Center

Liberal, Kansas, United States

Cancer Center of Kansas, PA - Newton

Newton, Kansas, United States

Menorah Medical Center

Overland Park, Kansas, United States

Saint Luke's Hospital - South

Overland Park, Kansas, United States

Cancer Center of Kansas, PA - Parsons

Parsons, Kansas, United States

Cancer Center of Kansas, PA - Pratt

Pratt, Kansas, United States

Cancer Center of Kansas, PA - Salina

Salina, Kansas, United States

Shawnee Mission Medical Center

Shawnee, Kansas, United States

Cancer Center of Kansas, PA - Wellington

Wellington, Kansas, United States

Associates in Womens Health, PA - North Review

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Medical Arts Tower

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Wichita

Wichita, Kansas, United States

CCOP - Wichita

Wichita, Kansas, United States

Via Christi Cancer Center at Via Christi Regional Medical Center

Wichita, Kansas, United States

Wesley Medical Center

Wichita, Kansas, United States

Cancer Center of Kansas, PA - Winfield

Winfield, Kansas, United States

Cancer Resource Center at King's Daughters Medical Center

Ashland, Kentucky, United States

Lucille P. Markey Cancer Center at University of Kentucky

Lexington, Kentucky, United States

Louisville Oncology at Norton Cancer Institute - Louisville

Louisville, Kentucky, United States

James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, United States

Mary Bird Perkins Cancer Center - Baton Rouge

Baton Rouge, Louisiana, United States

Ochsner Health Center - Bluebonnet

Baton Rouge, Louisiana, United States

MBCCOP - LSU Health Sciences Center

New Orleans, Louisiana, United States

Medical Center of Louisiana - New Orleans

New Orleans, Louisiana, United States

CCOP - Ochsner

New Orleans, Louisiana, United States

Ochsner Cancer Institute at Ochsner Clinic Foundation

New Orleans, Louisiana, United States

York Hospital's Oncology Treatment Center

York Village, Maine, United States

Greenebaum Cancer Center at University of Maryland Medical Center

Baltimore, Maryland, United States

Greater Baltimore Medical Center Cancer Center

Baltimore, Maryland, United States

St. Agnes Hospital Cancer Center

Baltimore, Maryland, United States

Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center

Baltimore, Maryland, United States

Frederick Memorial Hospital Regional Cancer Therapy Center

Frederick, Maryland, United States

Associates in Oncology and Hematology - Medical Center Drive

Rockville, Maryland, United States

Peninsula Regional Medical Center

Salisbury, Maryland, United States

MetroWest Medical Center - Framingham Union Hospital

Framingham, Massachusetts, United States

Hickman Cancer Center at Bixby Medical Center

Adrian, Michigan, United States

Saint Joseph Mercy Cancer Center

Ann Arbor, Michigan, United States

CCOP - Michigan Cancer Research Consortium

Ann Arbor, Michigan, United States

Oakwood Cancer Center at Oakwood Hospital and Medical Center

Dearborn, Michigan, United States

Josephine Ford Cancer Center at Henry Ford Hospital

Detroit, Michigan, United States

Genesys Hurley Cancer Institute

Flint, Michigan, United States

Hurley Medical Center

Flint, Michigan, United States

Great Lakes Cancer Institute at McLaren Regional Medical Center

Flint, Michigan, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center

Grosse Pointe Woods, Michigan, United States

Foote Memorial Hospital

Jackson, Michigan, United States

Borgess Medical Center

Kalamazoo, Michigan, United States

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Bronson Methodist Hospital

Kalamazoo, Michigan, United States

Haematology-Oncology Associates of Ohio and Michigan, PC

Lambertville, Michigan, United States

Breslin Cancer Center at Ingham Regional Medical Center

Lansing, Michigan, United States

Sparrow Regional Cancer Center

Lansing, Michigan, United States

Lapeer Regional Hospital

Lapeer, Michigan, United States

St. Mary Mercy Hospital

Livonia, Michigan, United States

Community Cancer Center of Monroe

Monroe, Michigan, United States

Mercy Memorial Hospital - Monroe

Monroe, Michigan, United States

St. Joseph Mercy Oakland

Pontiac, Michigan, United States

Mercy Regional Cancer Center at Mercy Hospital

Port Huron, Michigan, United States

Seton Cancer Institute at Saint Mary's - Saginaw

Saginaw, Michigan, United States

Lakeland Regional Cancer Care Center - St. Joseph

Saint Joseph, Michigan, United States

Lakeside Cancer Specialists, PLLC

Saint Joseph, Michigan, United States

Providence Cancer Institute at Providence Hospital - Southfield Campus

Southfield, Michigan, United States

St. John Macomb Hospital

Warren, Michigan, United States

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Mercy and Unity Cancer Center at Mercy Hospital

Coon Rapids, Minnesota, United States

Duluth Clinic Cancer Center - Duluth

Duluth, Minnesota, United States

CCOP - Duluth

Duluth, Minnesota, United States

Miller - Dwan Medical Center

Duluth, Minnesota, United States

Fairview Southdale Hospital

Edina, Minnesota, United States

Mercy and Unity Cancer Center at Unity Hospital

Fridley, Minnesota, United States

Hutchinson Area Health Care

Hutchinson, Minnesota, United States

HealthEast Cancer Care at St. John's Hospital

Maplewood, Minnesota, United States

Minnesota Oncology Hematology, PA - Maplewood

Maplewood, Minnesota, United States

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Minneapolis, Minnesota, United States

Hennepin County Medical Center - Minneapolis

Minneapolis, Minnesota, United States

Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center

Robbinsdale, Minnesota, United States

CCOP - Metro-Minnesota

Saint Louis Park, Minnesota, United States

Park Nicollet Cancer Center

Saint Louis Park, Minnesota, United States

Regions Hospital Cancer Care Center

Saint Paul, Minnesota, United States

United Hospital

Saint Paul, Minnesota, United States

St. Francis Cancer Center at St. Francis Medical Center

Shakopee, Minnesota, United States

Ridgeview Medical Center

Waconia, Minnesota, United States

Minnesota Oncology Hematology, PA - Woodbury

Woodbury, Minnesota, United States

Hattiesburg Clinic, PA at Forrest General

Hattiesburg, Mississippi, United States

Saint Francis Medical Center

Cape Girardeau, Missouri, United States

Ellis Fischel Cancer Center at University of Missouri - Columbia

Columbia, Missouri, United States

St. John's Regional Medical Center

Joplin, Missouri, United States

Truman Medical Center - Hospital Hill

Kansas City, Missouri, United States

Saint Luke's Cancer Institute at Saint Luke's Hospital

Kansas City, Missouri, United States

St. Joseph Medical Center

Kansas City, Missouri, United States

North Kansas City Hospital

Kansas City, Missouri, United States

Parvin Radiation Oncology

Kansas City, Missouri, United States

Heartland Hematology Oncology Associates, Incorporated

Kansas City, Missouri, United States

CCOP - Kansas City

Kansas City, Missouri, United States

Research Medical Center

Kansas City, Missouri, United States

Saint Luke's East - Lee's Summit

Lee's Summit, Missouri, United States

Liberty Hospital

Liberty, Missouri, United States

Heartland Regional Medical Center

Saint Joseph, Missouri, United States

CCOP - Cancer Research for the Ozarks

Springfield, Missouri, United States

St. John's Regional Health Center

Springfield, Missouri, United States

Hulston Cancer Center at Cox Medical Center South

Springfield, Missouri, United States

Midwest Hematology Oncology Group, Incorporated

St Louis, Missouri, United States

Saint Louis University Cancer Center

St Louis, Missouri, United States

CCOP - St. Louis-Cape Girardeau

St Louis, Missouri, United States

David C. Pratt Cancer Center at St. John's Mercy

St Louis, Missouri, United States

CCOP - Montana Cancer Consortium

Billings, Montana, United States

Hematology-Oncology Centers of the Northern Rockies - Billings

Billings, Montana, United States

Northern Rockies Radiation Oncology Center

Billings, Montana, United States

St. Vincent Healthcare Cancer Care Services

Billings, Montana, United States

Billings Clinic - Downtown

Billings, Montana, United States

Bozeman Deaconess Cancer Center

Bozeman, Montana, United States

St. James Healthcare Cancer Care

Butte, Montana, United States

Big Sky Oncology

Great Falls, Montana, United States

Great Falls Clinic - Main Facility

Great Falls, Montana, United States

Sletten Cancer Institute at Benefis Healthcare

Great Falls, Montana, United States

Great Falls, Montana, United States

St. Peter's Hospital

Helena, Montana, United States

Glacier Oncology, PLLC

Kalispell, Montana, United States

Kalispell Medical Oncology at KRMC

Kalispell, Montana, United States

Kalispell Regional Medical Center

Kalispell, Montana, United States

Community Medical Center

Missoula, Montana, United States

Guardian Oncology and Center for Wellness

Missoula, Montana, United States

Montana Cancer Specialists at Montana Cancer Center

Missoula, Montana, United States

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

Missoula, Montana, United States

Good Samaritan Cancer Center at Good Samaritan Hospital

Kearney, Nebraska, United States

Cancer Resource Center - Lincoln

Lincoln, Nebraska, United States

CCOP - Missouri Valley Cancer Consortium

Omaha, Nebraska, United States

Immanuel Medical Center

Omaha, Nebraska, United States

Alegant Health Cancer Center at Bergan Mercy Medical Center

Omaha, Nebraska, United States

Creighton University Medical Center

Omaha, Nebraska, United States

Cancer Institute of New Jersey at Hamilton

Hamilton, New Jersey, United States

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Cancer Institute of New Jersey at Cooper - Voorhees

Voorhees Township, New Jersey, United States

Charles R. Wood Cancer Center at Glens Falls Hospital

Glens Falls, New York, United States

Tucker Center for Cancer Care at Orange Regional Medical Center

Middletown, New York, United States

Saint Francis Hospital Cancer Center

Poughkeepsie, New York, United States

Our Lady of Mercy Medical Center Comprehensive Cancer Center

The Bronx, New York, United States

Randolph Hospital

Asheboro, North Carolina, United States

Hope A Women's Cancer Center

Asheville, North Carolina, United States

Alamance Cancer Center at Alamance Regional Medical Center

Burlington, North Carolina, United States

Blumenthal Cancer Center at Carolinas Medical Center

Charlotte, North Carolina, United States

Presbyterian Cancer Center at Presbyterian Hospital

Charlotte, North Carolina, United States

Batte Cancer Center at Northeast Medical Center

Concord, North Carolina, United States

Wayne Memorial Hospital, Incorporated

Goldsboro, North Carolina, United States

Moses Cone Regional Cancer Center at Wesley Long Community Hospital

Greensboro, North Carolina, United States

Annie Penn Cancer Center

Reidsville, North Carolina, United States

Rutherford Hospital

Rutherfordton, North Carolina, United States

Iredell Memorial Hospital

Statesville, North Carolina, United States

Marion L. Shepard Cancer Center at Beaufort County Hospital

Washington, North Carolina, United States

Forsyth Regional Cancer Center at Forsyth Medical Center

Winston-Salem, North Carolina, United States

Wake Forest University Comprehensive Cancer Center

Winston-Salem, North Carolina, United States

Altru Cancer Center at Altru Hospital

Grand Forks, North Dakota, United States

McDowell Cancer Center at Akron General Medical Center

Akron, Ohio, United States

Summa Center for Cancer Care at Akron City Hospital

Akron, Ohio, United States

Barberton Citizens Hospital

Barberton, Ohio, United States

Wood County Oncology Center

Bowling Green, Ohio, United States

Aultman Cancer Center at Aultman Hospital

Canton, Ohio, United States

Case Comprehensive Cancer Center

Cleveland, Ohio, United States

North Coast Cancer Care - Clyde

Clyde, Ohio, United States

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Grandview Hospital

Dayton, Ohio, United States

Good Samaritan Hospital

Dayton, Ohio, United States

David L. Rike Cancer Center at Miami Valley Hospital

Dayton, Ohio, United States

Samaritan North Cancer Care Center

Dayton, Ohio, United States

CCOP - Dayton

Dayton, Ohio, United States

Community Cancer Center

Elyria, Ohio, United States

Hematology Oncology Center

Elyria, Ohio, United States

Blanchard Valley Medical Associates

Findlay, Ohio, United States

Middletown Regional Hospital

Franklin, Ohio, United States

Wayne Hospital

Greenville, Ohio, United States

Charles F. Kettering Memorial Hospital

Kettering, Ohio, United States

Lima Memorial Hospital

Lima, Ohio, United States

Northwest Ohio Oncology Center

Maumee, Ohio, United States

St. Luke's Hospital

Maumee, Ohio, United States

Fisher-Titus Medical Center

Norwalk, Ohio, United States

St. Charles Mercy Hospital

Oregon, Ohio, United States

Toledo Clinic - Oregon

Oregon, Ohio, United States

Cancer Care Center, Incorporated

Salem, Ohio, United States

North Coast Cancer Care, Incorporated

Sandusky, Ohio, United States

Flower Hospital Cancer Center

Sylvania, Ohio, United States

Mercy Hospital of Tiffin

Tiffin, Ohio, United States

Toledo Hospital

Toledo, Ohio, United States

St. Vincent Mercy Medical Center

Toledo, Ohio, United States

Medical University of Ohio Cancer Center

Toledo, Ohio, United States

CCOP - Toledo Community Hospital

Toledo, Ohio, United States

St. Anne Mercy Hospital

Toledo, Ohio, United States

Toledo Clinic, Incorporated - Main Clinic

Toledo, Ohio, United States

UVMC Cancer Care Center at Upper Valley Medical Center

Troy, Ohio, United States

Fulton County Health Center

Wauseon, Ohio, United States

Clinton Memorial Hospital

Wilmington, Ohio, United States

Cancer Treatment Center

Wooster, Ohio, United States

Ruth G. McMillan Cancer Center at Greene Memorial Hospital

Xenia, Ohio, United States

Cleo Craig Cancer Research Clinic

Lawton, Oklahoma, United States

Kaiser Permanente Health Care - Portland

Portland, Oregon, United States

Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

Allentown, Pennsylvania, United States

St. Luke's Cancer Network at St. Luke's Hospital

Bethlehem, Pennsylvania, United States

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, United States

Geisinger Cancer Institute at Geisinger Health

Danville, Pennsylvania, United States

Cherry Tree Cancer Center

Hanover, Pennsylvania, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Cancer Center of Paoli Memorial Hospital

Paoli, Pennsylvania, United States

Allegheny Cancer Center at Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital

Pittsburgh, Pennsylvania, United States

UPMC Cancer Centers

Pittsburgh, Pennsylvania, United States

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center

Reading, Pennsylvania, United States

Geisinger Medical Group - Scenery Park

State College, Pennsylvania, United States

Mount Nittany Medical Center

State College, Pennsylvania, United States

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

Wilkes-Barre, Pennsylvania, United States

CCOP - Main Line Health

Wynnewood, Pennsylvania, United States

Lankenau Cancer Center at Lankenau Hospital

Wynnewood, Pennsylvania, United States

York Cancer Center at Apple Hill Medical Center

York, Pennsylvania, United States

AnMed Cancer Center

Anderson, South Carolina, United States

Roper St. Francis Cancer Center at Roper Hospital

Charleston, South Carolina, United States

Hollings Cancer Center at Medical University of South Carolina

Charleston, South Carolina, United States

CCOP - Greenville

Greenville, South Carolina, United States

CCOP - Upstate Carolina

Spartanburg, South Carolina, United States

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States

Medical X-Ray Center, PC

Sioux Falls, South Dakota, United States

Sanford Cancer Center at Sanford USD Medical Center

Sioux Falls, South Dakota, United States

Thompson Cancer Survival Center

Knoxville, Tennessee, United States

University of Tennessee Cancer Institute - Memphis

Memphis, Tennessee, United States

Nashville Oncology Associates, PC

Nashville, Tennessee, United States

MBCCOP - Meharry Medical College - Nashville

Nashville, Tennessee, United States

Doctor's Hospital of Laredo

Laredo, Texas, United States

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

American Fork Hospital

American Fork, Utah, United States

Sandra L. Maxwell Cancer Center

Cedar City, Utah, United States

Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

Murray, Utah, United States

Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

Ogden, Utah, United States

Utah Valley Regional Medical Center - Provo

Provo, Utah, United States

LDS Hospital

Salt Lake City, Utah, United States

Utah Cancer Specialists at UCS Cancer Center

Salt Lake City, Utah, United States

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States

Dixie Regional Medical Center - East Campus

St. George, Utah, United States

Mountainview Medical

Berlin Corners, Vermont, United States

Fletcher Allen Health Care - University Health Center Campus

Burlington, Vermont, United States

Fredericksburg Oncology, Incorporated

Fredericksburg, Virginia, United States

Virginia Commonwealth University Massey Cancer Center

Richmond, Virginia, United States

Auburn Regional Center for Cancer Care

Auburn, Washington, United States

Providence Centralia Hospital

Centralia, Washington, United States

St. Francis Hospital

Federal Way, Washington, United States

Providence St. Peter Hospital Regional Cancer Center

Olympia, Washington, United States

Good Samaritan Cancer Center

Puyallup, Washington, United States

Franciscan Cancer Center at St. Joseph Medical Center

Tacoma, Washington, United States

Allenmore Hospital

Tacoma, Washington, United States

CCOP - Northwest

Tacoma, Washington, United States

MultiCare Regional Cancer Center at Tacoma General Hospital

Tacoma, Washington, United States

St. Clare Hospital

Tacoma, Washington, United States

West Virginia University Health Sciences Center - Charleston

Charleston, West Virginia, United States

Mary Babb Randolph Cancer Center at West Virginia University Hospitals

Morgantown, West Virginia, United States

Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital

Parkersburg, West Virginia, United States

Marshfield Clinic - Chippewa Center

Chippewa Falls, Wisconsin, United States

Marshfield Clinic Cancer Care at Regional Cancer Center

Eau Claire, Wisconsin, United States

Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center

Green Bay, Wisconsin, United States

Gundersen Lutheran Center for Cancer and Blood

La Crosse, Wisconsin, United States

Marshfield Clinic - Marshfield Center

Marshfield, Wisconsin, United States

Saint Joseph's Hospital

Marshfield, Wisconsin, United States

Aurora Sinai Medical Center

Milwaukee, Wisconsin, United States

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States

Marshfield Clinic - Lakeland Center

Minocqua, Wisconsin, United States

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, United States

Ministry Medical Group at Saint Mary's Hospital

Rhinelander, Wisconsin, United States

Marshfield Clinic - Indianhead Center

Rice Lake, Wisconsin, United States

Marshfield Clinic at Saint Michael's Hospital

Stevens Point, Wisconsin, United States

Marshfield Clinic - Wausau Center

Wausau, Wisconsin, United States

Aurora Women's Pavilion of West Allis Memorial Hospital

West Allis, Wisconsin, United States

Marshfield Clinic - Weston Center

Weston, Wisconsin, United States

Marshfield Clinic - Wisconsin Rapids Center

Wisconsin Rapids, Wisconsin, United States

Welch Cancer Center at Sheridan Memorial Hospital

Sheridan, Wyoming, United States

Edmond Odette Cancer Centre at Sunnybrook

Toronto, Ontario, Canada

Hopital Notre-Dame du CHUM

Montreal, Quebec, Canada

CHUM - Hotel Dieu Hospital

Montreal, Quebec, Canada

CHUM - Hopital Saint-Luc

Montreal, Quebec, Canada

Royal Victoria Hospital - Montreal

Montreal, Quebec, Canada

Montreal General Hospital

Montreal, Quebec, Canada

Jewish General Hospital - Montreal

Montreal, Quebec, Canada

St. Mary's Hospital Center

Montreal, Quebec, Canada

Hopital du Saint-Sacrement - Quebec

Québec, Quebec, Canada

San Juan City Hospital

San Juan, , Puerto Rico

Countries

United States; Canada; Puerto Rico

References

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. doi: 10.1056/NEJMoa1111097.

Reference Type: RESULT

PMID: 22276821 (View on PubMed)

Bear HD, Tang G, Rastogi P, et al.: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. [Abstract] J Clin Oncol 29 (Suppl 15): A-LBA1005, 2011.

Reference Type: RESULT

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10.

Reference Type: DERIVED

PMID: 26272770 (View on PubMed)

Other Identifiers

NSABP B-40

Identifier Type: -

Identifier Source: secondary_id

NSABP B-40

Identifier Type: -

Identifier Source: org_study_id